Oxfendazole_COA_12977_MedChemExpress

合集下载

XMD8-87_DataSheet_MedChemExpress

Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:XMD8–87 is a potent TNK2 inhibitor with IC 50 values of 38 and 113 nM for the D163E and R806Q mutations, respectively.IC50 & Target: IC50: 38 nM (TNK2, D163E mutation), 113 nM (TNK2, R806Q mutation)[1]In Vitro: XMD8–87 potently inhibits the growth of the TNK2 mutant expressing cell lines while having little or no effect on the control cells out to the highest tested concentrations (1,000 nM). XMD8–87 has IC 50s of 38 nM and 113 nM for the D163E and R806Q mutations. The effects of XMD8–87 on TNK2 cell lines are largely due to on–target effects on TNK2. Auto–phosphorylation of overexpressed TNK2 mutants could be blocked with TNK2 inhibitor XMD8–87[1].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Kinase targets are tested with biochemical enzymatic kinase assays using the SelectScreen Kinase Profiling Service to determine IC 50 values. The compounds (XMD8–87) are assayed at 10 concentrations (3–fold serial dilutions starting from 1 μM) at an ATP concentration equal to the ATP Km [1].Cell Assay:[1]Cells are treated with the following inhibitors for 72 hours: dasatinib, AIM–100, XMD8–87 and XMD16–5. Cell viability is measured using a methanethiosulfonate (MTS)–based assay and absorbance (490 nm) is read at 1 and 3 hours after adding reagent [1].References:[1]. Maxson JE, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.Product Name:XMD8–87Cat. No.:HY-15811CAS No.:1234480-46-6Molecular Formula:C 24H 27N 7O 2Molecular Weight:445.52Target:Tyrosinase Pathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 26 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

分子生物学词汇(中英文对照表 )

Gelucire-14-44-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

210996952_伏诺拉生治疗胃食管反流有效性和安全性的Meta分析

中国药房
robust and the possibility of publication bias was small.
CONCLUSIONS Vonoprazan has a considerable effectiveness
and safety in the treatment of gastroesophageal reflux disease.
of treatment （P＜0.05）. The results of sensitivity analysis and publication bias analysis showed that the results of this study were
Δ 基金项目四川省区域创新合作项目（No.2020YFQ0010）
Mei，ZHENG
Minglin，FAN
Ping（Dept. of
Pharmacy，West China Hospital of Sichuan University，Chengdu 610041，China）
ABSTRACT
OBJECTIVE To systematically evaluate the efficacy and safety of vonoprazan in the treatment of gastroesophageal
愈率，不同洛杉矶分级治愈率；安全性指标包括：药物不
化系统疾病。流行病学资料显示，GERD 患病率在全
良事件、腹泻、鼻咽炎、上呼吸道感染、碱性磷酸酶升高
球范围内呈上升趋势，西方国家为 10%～20%，我国为
发生率。
[1]
1.9%～7.0% 。GERD 的典型症状包括烧心（胃灼热）和

放线菌素D

结晶性取本品少许，依法检查（通则0981），应符合规定。有关物质照高效液相色谱法（通则0512）测定，临用新制，避光操作。溶剂：乙腈-水（60:40）。供试品溶液：取本品约20mg，精密称定，置100mL棕色量瓶中，加溶剂溶解并稀释至刻度，摇匀。对照溶液：精密量取供试品溶液1mL，置100mL棕色量瓶中，用溶剂稀释至刻度，摇匀。系统适用性溶液：取放线菌素D对照品适量，加溶剂溶解并稀释制成每1mL中约含0.2mg的溶液。色谱条件：用十八烷基硅烷键合硅胶为填充剂（4.6mm×250mm，5µm或效能相当的色谱柱），以醋酸盐缓冲液（取醋酸钠2.72g与醋酸2mL，加水溶解并稀释至1000mL）-乙腈（51:49）为流动相A，以上述醋酸盐缓冲液乙腈（20:80）为流动相B，按下表进行线性梯度洗脱，流速为每分钟1.5mL，检测波长为254nm，进样体积100µL。系统适用性要求：系统适用性溶液色谱图应与标准图谱一致，放线菌素D与杂质Ⅰ间的分离度应符合规定。
有消化道反应、骨髓抑制，少数患者有脱发、皮炎、发热及肝功能损伤等。
骨髓功能低下，有痛风病史，肝功能损害，感染，有尿酸盐性肾结石病史，近期接受过放射治疗或抗癌药治疗者慎用。用药期间应严格检查血象。定期查肝肾功能。毒副作用出现后可考虑减量或停药。注射时防止药液漏出血管外。本品可能使尿及血内尿酸升高。
对本品过敏者、孕妇、有水痘病史者、严重骨髓抑制者、严重肝肾功能损害者禁用。
本品可提高放射敏感性，与放射治疗同时应用，可能加重放射治疗降低白细胞作用和局部组织损害作用。本品也可能削弱维生素K的疗效。
说明：上述内容仅作为介绍，药物使用必须经正规医院在医生指导下进行。
药典信息
来源性状
鉴别检查
R28：Very toxic if swallowed. 吞食有极高毒性。 R40：Possible risks of irreversible effects. 可能有不可逆作用的风险。 R61：May cause harm to the unborn child. 可能对未出生婴儿造成危害。

商陆正丁醇部位醋制前后肠道毒性变化研究

商陆正丁醇部位醋制前后肠道毒性变化研究为探索商陆毒性部位炮制前后对肠道毒性变化的影响，提取分离获得了商陆正丁醇毒性部位，在整体动物模型水平，灌胃给药后观察小鼠肠道肿胀程度，测定小鼠肠道不同部位的含水量及粪便的含水量，考察商陆正丁醇部位炮制前后对腹泻及肠道肿胀的影响；在细胞水平，采用MTT法，测定肠细胞HT-29，IEC-6的IC50，比较醋制前后商陆正丁醇部位的毒性变化。

结果显示商陆正丁醇部位能够导致肠道肿胀，表现为引起十二指肠、空肠的水肿，且可导致粪便含水量增加引起腹泻，可抑制肠细胞HT-29，IEC-6增殖，表明其具有肠细胞毒性，对HT-29细胞的IC5014.59 mg·L-1，IEC-6 IC5043.77 mg·L-1；经醋制，小鼠肠道肿胀程度显著减弱，肠道和粪便的含水量明显降低，对HT-29和IEC-6的抑制作用减轻，对HT-29细胞的IC5058.51mg·L-1，IEc-6 IC5084.37mg·L-1。

由此可知，醋制法具有降低商陆正丁醇部位的毒性作用。

标签：商陆；正丁醇部位；肠道水肿；腹泻；肠细胞增殖抑制；醋制减毒中药商陆为商陆科植物商陆Phytolacca acinosaRoxb.或垂序商陆P.americama L的干燥根。

商陆味苦、寒，有毒，归肺、脾、肾、大肠经。

有逐水消肿，通利二便的功能。

主治水肿胀满、二便不通。

用于水肿尿少，腹水胀满，外治外伤出血、痈肿疮毒等。

商陆药性峻猛，有大毒，可对胃肠道黏膜产生强烈的刺激，表现为恶心、呕吐、腹痛、腹泻，严重者可导致呕血、便血，故临床上需炮制后应用。

商陆生品粉末可引起家兔眼结膜强烈水肿，提取液能够刺激巨噬细胞释放炎症因子，醋制后毒性明显下降。

课题组前期研究发现商陆正丁醇萃取部位具有强烈的刺激性，是商陆的主要毒性部位。

本实验建立整体及细胞水平的毒性评价模型，比较商陆正丁醇部位模拟醋制前后对肠道毒性的变化，为商陆醋制解毒机制的研究奠定基础。

美国Medchemexpress化合物库(小分子库)_Medchemexpress_(MCE中国)

美国Medchemexpress化合物库（小分子库）-原装进口，现货供
应，提供组合定制服务
品牌：Medchemexpress （MCE）
保存条件：-20℃
供应商：MCE中国
数量：大量
保质期：2年
Size：
Pre-dissolved DMSO/Solid（Or dry solid）
100 uL/well (10 mM solution)
200 uL/well (10 mM solution)
MedChemExpress (MCE)专注于各种抑制剂、调节剂、API、天然产物及化合物库，总部位于美国新泽西。

MCE经过十年努力已成为全球生物活性小分子领域的一流供应商。

MedChemExpress(MCE)产品涵盖近20个热门研究领域，1000多个细分靶点，超过3000个现货抑制剂、拮抗剂和激动剂。

相关的应用成果已发表于Nature、Cell等国际知名杂志，在全球20余个国家地区设有代理机构。

上海皓元生物医药科技有限公司(MCE 中国) 是MedChemExpress (MCE) 亚洲总代理。

MCE化合物库涵盖20余种不同的类型，超过2500个化合物，进口原装，
现货供应，提供详实的生物活性信息、化学结构信息、质控图谱（NMR和HPLC 等）。

还可根据您的实际研究需要，为您度身定制任意组合、规格、布板的特殊化合物库。

/screening-libraries.html
现有特色化合物库有：。

抗体公司

赛信通（上海）生物试剂有限公司
上海市浦东南路1101号远东大厦514室，200120 info@cst www.cst 2158356288 公司总部: 美国
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privatelyowned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activationstate and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine. 总引用数为4670，来自于1966篇文章。最常引用的试剂包括： Akt, ERK2, ERK1, p38, Akt1。
AbD Serotec (BioRad)

阿司咪唑

合成方法
合成方法
化合物(I)和碘甲烷在乙醇中回流8h，环合得到化合物(Ⅱ)。再水解脱去酯基，得到化合物(Ⅲ)。用对甲氧基苯乙基溴进行N-烷基化，得化合物(Ⅳ)。再用对氟苄基溴烷基化，得阿司咪唑。
1. 1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮的制备
在反应瓶中加入2-羟基苯并咪唑5.0g(37.3mmol)和NaH 1.6g(53mmol)(NaH含量大约为80%,浸入矿物油中) 的DMF 100ml的悬浮液.加毕.在60ºC.(最好有N2保护)搅拌反应1h.再加入4-氟苄基氯(FBC)5.4g(37mmol),加热 ( 6 0 ºC ) 搅拌反应 5 . 5 h . 冷却至室温后加入冰水 7 0 0 m l , 用二氯甲烷 ( 5 0 0 m l × 2 ) 提取 . 有机层用食盐水洗 . 无水 N a 2 S O 4 干燥.过滤.滤液减压浓缩.剩余物用石油醚析晶.得1-[(4-氟苯基)甲基]-苯并咪唑-2-(3H)-酮固体8.0g,为无色结晶 m p 1 7 8 ~ 1 7 9 ºC , 收率 8 8 % .
治疗措施
阿司咪唑中毒的治疗要点为： 1.大量摄入者予洗胃，后灌服活性炭和导泻。 2.对心肌抑制和Q-T间期延长者予5%碳酸氢钠250ml静注可能有效。 3.对症、支持治疗。
专家点评
专家点评
阿司咪阿司咪唑自1983年上市以来，在许多国家得到了广泛应用。国外研究显示阿司咪唑治疗荨麻疹的总有效率为74%。国内的一项多中心双盲安慰剂对照试验表明阿司咪唑对急性荨麻疹的总有效率为82.9%，对慢性荨麻疹的总有效率为86.0%，均显著高于安慰剂，主要不良反应为嗜睡、倦怠、口干等，连续用药3个月的患者中，半数有食欲及体重增加。阿司咪唑的心脏毒性虽然发生率较低，但由于后果严重，已限制了它的应用。阿司咪唑为强效和长效的H1受体拮抗剂，无中枢镇静和抗毒蕈碱样作用。代谢产物去甲阿司咪唑仍有抗胆胺作用。长期服用可增进食欲和增加体重，服用过量可引起心脏Q-T间期延长和室性心律失常。适用于各种原因引起过敏性疾病。

Calcipotriol_SDS_MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Sep.-13-2017Print Date:Sep.-13-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :CalcipotriolCatalog No. :HY-10001CAS No. :112965-21-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:MC 903; CalcipotrieneFormula:C27H40O3Molecular Weight:412.60CAS No. :112965-21-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature: 4°C, protect from light, stored under nitrogenShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

依达拉奉右莰醇通过铁死亡-脂质过氧化通路对脑出血大鼠神经保护的作用机制

实验研究依达拉奉右莰醇通过铁死亡-脂质过氧化通路对脑出血大鼠神经保护的作用机制毛权西，李作孝△摘要：目的探讨依达拉奉右莰醇对脑出血大鼠的神经保护作用及血肿周围脑组织脂质过氧化的影响。

方法将128只SD大鼠随机分为假手术组、脑出血组、依达拉奉组和依达拉奉右莰醇组，每组32只。

除假手术组外，其余组大鼠构建急性脑出血模型，依达拉奉组、依达拉奉右莰醇组于造模后分别腹腔注射依达拉奉6mg/kg、依达拉奉右莰醇7.5mg/kg，每12h注射1次，假手术组和脑出血组腹腔注射等量生理盐水。

术后1d、3d、7d和14d按Garcia评分标准进行神经功能评分，HE染色观察血肿周围脑组织病理变化，化学荧光法检测血肿周围脑组织活性氧（ROS）含量，微量酶标法检测血肿周围脑组织还原型谷胱甘肽（GSH）含量，蛋白免疫印迹法检测血肿周围脑组织谷胱甘肽过氧化物酶4（GPX4）、长链脂酰辅酶A合成酶4（ACSL4）和磷脂胆碱酰基转移酶3（LPCAT3）表达。

结果与假手术组比较，脑出血组大鼠神经功能评分降低，血肿周围脑组织出现大量炎性细胞浸润及神经细胞变性，ROS含量、ACSL4和LPCAT3蛋白表达水平升高，GSH含量、GPX4蛋白表达水平降低（P＜0.05）；与脑出血组比较，依达拉奉组和依达拉奉右莰醇组大鼠神经功能评分升高，血肿周围脑组织病理损伤明显减轻，ROS含量、ACSL4和LPCAT3蛋白表达水平降低，GSH含量、GPX4蛋白表达水平增加（P＜0.05）；依达拉奉右莰醇组干预效果优于依达拉奉组（P＜0.05）；除假手术组外，其余各组均在术后3d时变化最明显，术后7d、14d逐渐恢复（P＜0.05）。

结论依达拉奉右莰醇可能通过调节脑出血大鼠神经细胞铁死亡相关蛋白的表达，减少脑组织脂质过氧化，抑制神经细胞铁死亡，从而发挥脑保护作用。

关键词：依达拉奉右莰醇；依达拉奉；脑出血；铁死亡；脂质过氧化中图分类号：R743.34文献标志码：A DOI：10.11958/20221777Neuroprotective mechanism of edaravone dexborneol in rats with cerebral hemorrhage throughferroptosis-lipid peroxidation pathwayMAO Quanxi,LI Zuoxiao△Department of Neurology,the Affiliated Hospital of Southwest Medical University,Luzhou646000,China△Corresponding Author E-mail:Abstract:Objective To investigate the neuroprotective effect of edaravone dexborneol on cerebral hemorrhage in rats and the effect of lipid peroxidation on perihematomal brain tissue.Methods A total of128SD rats were randomly divided into the sham-operated group,the cerebral hemorrhage group,the edaravone group and the edaravone dexborneol group, with32rats in each group.The acute cerebral hemorrhage model was constructed in all groups except for the sham-operated group.The edaravone group and edaravone dexamphene group were injected intraperitoneally with6mg/kg of edaravone and edaravone dexamphene7.5mg/kg,one injection every12hours.The sham-operated group and the cerebral hemorrhage group were injected intraperitoneally with equal amounts of saline.The neurological function was scored according to Garcia score at1d,3d,7d,and14d after surgery.Brain tissue around hematoma was stained with HE staining.Chemo fluorescence assay was used to observe pathological changes and reactive oxygen species(ROS)content of brain tissue around hematoma.Micro enzyme labeling assay was used to detect glutathione(GSH)content of brain tissue around hematoma.The expression levels of glutathione peroxidase4(GPX4),long-chain lipid acyl-coenzyme A synthase4(ACSL4) and phospholipid choline acyltransferase3(LPCAT3)in brain tissue around hematoma were detected by protein immunoblotting.Results Compared with the sham-operated group,neurological function scores were decreased in the cerebral hemorrhage group.Massive inflammatory cell infiltration and neuronal degeneration in brain tissue around hematoma were found,and ROS content,ACSL4and LPCAT3protein expression level increased.GSH content and GPX4 protein expression level decreased in the cerebral hemorrhage group(P＜0.05).Compared with the cerebral hemorrhage group,neurological function scores were increased,histopathological damage around the hematoma was significantly基金项目：泸州市人民政府-西南医科大学科技战略合作基金项目（2018LZXNYD-ZK17）作者单位：西南医科大学附属医院神经内科（邮编646000）作者简介：毛权西（1990），男，硕士在读，主要从事神经免疫方向研究。

OXOID药敏纸片中英文对照

AAmikacin 阿米卡星（丁胺卡那霉素）AK 30µg CT0107B Amoxycillin 阿莫西林（羟氨苄青霉素）AML 2µg CT0060B Amoxycillin 阿莫西林（羟氨苄青霉素）AML 10µg CT0161B Amoxycillin 阿莫西林（羟氨苄青霉素）AML 25µg CT0061BAmoxycillin/clavulanic acid 阿莫西林／克拉维酸（棒酸）（2:1）（澳格门汀）AMC 3µg CT0538BAmoxycillin/clavulanic acid 阿莫西林／克拉维酸（棒酸）（2:1）（澳格门汀）AMC 30µg CT0223BAmpicillin 氨苄西林AMP 2µg CT0002B Ampicillin 氨苄西林AMP 10µg CT0003B Ampicillin 氨苄西林AMP 25µg CT0004B Ampicillin/sulbactam 1:1 氨苄西林/舒巴坦（1:1）SAM 20µg CT0520B Ampicillin/sulbactam 2:1 氨苄西林/舒巴坦（2:1）SAM 30µg CT1653B Apramycin 阿泊拉霉素（安普霉素）APR 15µg CT0545B Azithromycin 阿齐霉素（阿奇霉素）AZM 15µg CT0906B Aztreonam 安曲南ATM 30µg CT0264B BBacitracin 杆菌肽 B 10 units CT0005B CCarbenicillin 羧苄西林（羧苄青霉素）CAR 100µg CT0006B Cefaclor 头孢克洛（头孢克罗）CEC 30µg CT0149B Cefadroxil 头孢羟氨苄CFR 30µg CT0453B Cefamandole 头孢孟多MA 30µg CT0108B Cefepime 头孢吡肟（马斯平）FEP 30µg CT0771B Cefixime 头孢克肟（世福素）CFM 5µg CT0653B Cefoperazone 头孢哌酮（先锋必）CFP 30µg CT0193B Cefoperazone 头孢哌酮（先锋必）CFP 75µg CT0249BCefoperazone/sulbactam 2:1 头孢哌酮／舒巴坦（2：1）（舒普深）SCF 105µg CT1727BCefotaxime 头孢噻肟（凯福隆）CTX 5µg CT0407B Cefotaxime 头孢噻肟（凯福隆）CTX 30µg CT0166B Cefotetan 头孢替坦CTT 30µg CT0665B Cefoxitin 头孢西丁（美福仙）FOX 30µg CT0119B Cefpirome 头孢匹罗CPO 30µg CT1412B Cefpodoxime 头孢泊肟CPD 10µg CT1612B Cefprozil 头孢丙烯CPR 30µg CT1647B Cefsulodin 头孢磺胺（达克舒林）CFS 30µg CT0263B Ceftazidime 头孢他啶CAZ 10µg CT1629B Ceftazidime 头孢他啶CAZ 30µg CT0412B Ceftibuten 头孢布烯CFT 30µg CT1662B Ceftiofur 头孢噻呋EFT 30µg CT1751B Ceftizoxime 头孢唑肟（安保速灵）ZOX 30µg CT0477BCeftriaxone 头孢曲松（头孢三嗪）CRO 30µg CT0417B Cefuroxime sodium 头孢呋新钠CXM 5µg CT0406B Cefuroxime sodium 头孢呋新钠CXM 30µg CT0127B Cephalexin 头孢氨苄（头孢力新，先锋IV）CL 30µg CT0007B Cephalothin 头孢噻吩（头孢菌素，先锋I ）KF 30µg CT0010B Cephazolin 头孢唑啉（先锋V）KZ 30µg CT0011B Cephradine 头孢拉定（先锋VI）CE 30µg CT0063B Chloramphenicol 氯霉素 C 10µg CT0012B Chloramphenicol 氯霉素 C 30µg CT0013B Chloramphenicol 氯霉素 C 50µg CT0014B Cinoxacin 西诺沙星CIN 100µg CT0162B Ciprofloxacin 环丙沙星（悉复欢）CIP 1µg CT0623B Ciprofloxacin 环丙沙星（悉复欢）CIP 5µg CT0425B Ciprofloxacin 环丙沙星（悉复欢）CIP 10µg CT1615B Clarithromycin 克拉霉素CLR 2µg CT1599B Clarithromycin 克拉霉素CLR 5µg CT1623B Clarithromycin 克拉霉素CLR 15µg CT0693BClindamycin 克林霉素（氯林可霉素，氯洁霉素）DA 2µg CT0064BClindamycin 克林霉素（氯林可霉素，氯洁霉素）DA 10µg CT0015BCloxacillin 氯唑西林（邻氯青霉素）OB 5µg CT0016B Colistin sulphate 多粘菌素E（硫酸粘杆菌素）CT 10µg CT0017B Colistin sulphate 多粘菌素E（硫酸粘杆菌素）CT 25µg CT0065B Colistin sulphate 多粘菌素E（硫酸粘杆菌素）CT 50µg CT0664B Compound sulphonamides 磺胺复合物S3 300µg CT0059B 抗生素英文名全称中文名全称名称缩写浓度产品编号DDoxycycline 强力霉素DO 30µg CT0018B EEnrofloxacin 恩诺沙星ENR 5µg CT0639B Ertapenem 厄他培南ETP 10µg CT1761B Erythromycin 红霉素 E 5µg CT0066B Erythromycin 红霉素 E 10µg CT0019B Erythromycin 红霉素 E 15µg CT0020B Erythromycin 红霉素 E 30µg CT0021B抗生素英文名全称中文名全称名称缩写浓度产品编号FFlorfenicol 氟苯尼考FFC 30µg CT1754BFluconazole 氟康唑FCA 25µg CT1806B Flumequine 氟甲喹UB 30µg CT0666B Fosfomycin 磷霉素FOS 50µg CT0183B 抗生素英文名全称中文名全称名称缩写浓度产品编号Framycetin 新霉素B FY 100µg CT0071B Fusidic acid 褐霉素（夫西地酸）FD 5µg CT0493B Fusidic acid 褐霉素（夫西地酸）FD 10µg CT0023B Fusidic acid 褐霉素（夫西地酸）FD 50µg CT1617B GGentamicin 庆大霉素CN 10µg CT0024B Gentamicin 庆大霉素CN 30µg CT0072B Gentamicin 庆大霉素CN 120µg CT0794B Gentamicin 庆大霉素CN 200µg CT0695B IImipenem 亚胺培南（配能）IPM 10µg CT0455B KKanamycin 卡那霉素K 5µg CT0025B Kanamycin 卡那霉素K 30µg CT0026B LLatamoxef 拉氧头孢MOX 30µg CT0302B Levofloxacin 左氧氟沙星（可乐必妥）LEV 1µg CT1586B Levofloxacin 左氧氟沙星（可乐必妥）LEV 5µg CT1587B Lincomycin 林可霉素（洁霉素）MY 2µg CT0027B Lincomycin 林可霉素（洁霉素）MY 10µg CT0123B Lincomycin 林可霉素（洁霉素）MY 15µg CT0028BLincomycin/neomycin 林可霉素（洁霉素）/新霉素LN 75µg CT1757BLincomycin/spectinomycin 林可霉素/壮观霉素LS 109µg CT1758B Linezolid 利奈唑胺LZD 10µg CT1649B Linezolid 利奈唑胺LZD 30µg CT1650B Lomefloxacin 洛美沙星LOM 10µg CT1661B MMecillinam 美西林MEL 10µg CT0096B Mecillinam 美西林MEL 25µg CT0091B Meropenem 美罗培南（美平）MEM 10µg CT0774B Metronidazole 甲硝唑（灭滴灵）MTZ 5µg CT0067B Metronidazole 甲硝唑（灭滴灵）MTZ 50µg CT0466B Mezlocillin 美洛西林MEZ 30µg CT0174B Mezlocillin 美洛西林MEZ 75µg CT0192BMinocycline 米诺环素（二甲胺四环素）MH 30µg CT0030BMoxalactam 拉氧头孢MOX 30µg CT0302B Moxifloxacin 莫西沙星MXF 1µg CT1683B Moxifloxacin 莫西沙星MXF 5µg CT1633BMupirocin 莫匹罗星MUP 5µg CT0522B Mupirocin 莫匹罗星MUP 20µg CT1826B Mupirocin 莫匹罗星MUP 200µg CT0523B NNalidixic acid 萘啶酸NA 30µg CT0031B 抗生素英文名全称中文名全称名称缩写浓度产品编号Neomycin 新霉素N 30µg CT0033BNetilmicin 奈替米星（乙基西梭霉素）NET 10µg CT0424BNetilmicin 奈替米星（乙基西梭霉素）NET 30µg CT0225BNitrofurantoin 呋喃妥因（呋喃妥英） F 50µg CT0069B Nitrofurantoin 呋喃妥因（呋喃妥英） F 100µg CT0034B Nitrofurantoin 呋喃妥因（呋喃妥英） F 200µg CT0035B Nitrofurantoin 呋喃妥因（呋喃妥英） F 300µg CT0036B Norfloxacin 诺氟沙星（氟哌酸）NOR 2µg CT0687B Norfloxacin 诺氟沙星（氟哌酸）NOR 5µg CT0668B Norfloxacin 诺氟沙星（氟哌酸）NOR 10µg CT0434B Novobiocin 新生霉素NV 5µg CT0037B Novobiocin 新生霉素NV 30µg CT0038B Nystatin 制霉菌素NS 100units CT0073B OOfloxacin 氧氟沙星（泰利必妥）OFX 5µg CT0446B Oleandomycin 竹桃霉素OL 15µg CT0039B Oxacillin 苯唑西林OX 1µg CT0159B Oxacillin 苯唑西林OX 5µg CT0040B Oxolinic acid 奥索利酸（恶喹酸）OA 2µg CT0181BOxytetracycline 土霉素（氧四环素，地霉素）OT 30µg CT0041BPPefloxacin 培氟沙星（甲氟哌酸）PEF 5µg CT0661B Penicillin G 青霉素G P 1unit CT0152B Penicillin G 青霉素G P 1.5unit CT0042B Penicillin G 青霉素G P 2units CT0088B Penicillin G 青霉素G P 5units CT0124B Penicllin G 青霉素G P 10units CT0043B Penicillin/novobiocin 青霉素/新生霉素PNV 40 CT1755B Pipemidic acid 吡哌酸PIP 20µg CT0180BPiperacillin 哌拉西林（氧哌嗪青霉素）PRL 30µg CT1619BPiperacillin 哌拉西林（氧哌嗪青霉素）PRL 75µg CT0261BPiperacillin 哌拉西林（氧哌嗪青霉素）PRL 100µg CT0199BPiperacillin/tazobactam 哌拉西林/他唑巴坦（特治星）TZP 36µg CT1616B Piperacillin/tazobactam 哌拉西林/他唑巴坦（特治星）TZP 40µg CT1628B Piperacillin/tazobactam 哌拉西林/他唑巴坦（特治星）TZP 85µg CT0720B Piperacillin/tazobactam 哌拉西林/他唑巴坦（特治星） TZP 110µg CT0725B Pirlimycin 吡利霉素 PIR 2µg CT1668B Polymyxin B多粘菌素BPB300units CT0044BQQuinupristin/dalfopristin 喹奴普汀/达福普汀 QD 15µg CT1644BR抗生素英文名全称中文名全称名称缩写浓度产品编号 Rifampicin 利福平 RD 2µg CT0078B Rifampicin 利福平 RD 5µg CT0207B Rifampicin 利福平 RD 30µg CT0104BSSpectinomycin 大观霉素（壮观霉素） SH 10µg CT0046B Spectinomycin 大观霉素（壮观霉素） SH 25µg CT0411B Spectinomycin 大观霉素（壮观霉素） SH 100µg CT0823B Spiramycin 螺旋霉素 SP 100µg CT0232B Streptomycin 链霉素 S 10µg CT0047B Streptomycin链霉素 S 25µg CT0048B Sulbactam/ampicillin 1 : 1舒巴坦/氨苄西林 SAM 20µg CT0520BSulbactam/ampicillin 1 : 2 舒巴坦/氨苄西林（优立新） SAM 30µg CT1653B Sulphafurazole 磺胺异恶唑 SF300µg CT0075B Sulphamethoxazole 磺胺甲基异恶唑（新诺明） RL25µg CT0051B Sulphamethoxazole 磺胺甲基异恶唑（新诺明） RL 100µg CT0074B Sulphamethoxazole/trimethoprim 19 : 1 磺胺甲基异恶唑（新诺明）/甲氧苄氨嘧啶 SXT 25µg CT0052B Sulphonamides compound 磺胺复合物 S3 300µg CT0059BT Teicoplanin 替考拉宁（壁霉素） TEC 30µg CT0647B Telithromycin 泰利霉素 TEL 15µg CT1714B Tetracycline 四环素 TE 10µg CT0053B Tetracycline 四环素 TE 30µg CT0054B Ticarcillin 替卡西林（羧噻吩青霉TIC75µgCT0167B素）Ticarcillin/clavulanic acid 7.5 : 1 替卡西林／克拉维酸（7.5:1） TIM 85µg CT0449B Tigecycline 替加环素 TGC 15µg CT1841B Tilmicosin 替米考星 TIL 15µg CT1756B Tobramycin 妥布霉素（托普霉素） TOB 10µg CT0056B Tobramycin 妥布霉素（托普霉素） TOB 30µg CT1618B Trimethoprim 甲氧苄氨嘧啶 W 1.25µg CT0057B Trimethoprim 甲氧苄氨嘧啶 W 2.5µg CT0070B Trimethoprim 甲氧苄氨嘧啶 W 5µg CT0076B Trimethoprim/sulphamethoxazole 1:19 甲氧苄氨嘧啶/磺胺甲基异恶唑（复方新诺明） SXT 25µg CT0052B V Vancomycin 万古霉素（稳可信） VA 5µg CT0188B Vancomycin 万古霉素（稳可信） VA 30µg CT0058B Voriconazole 优立康唑 VOR 1µg CT1807B 注释： CLSI: Clinical ａnd Laboratory Standards Institute 美国临床实验室标准化研究所DIN: Deutsches Institut f ür Normung 德国标准化学会 BSAC: British Society for Antimicrobial Chemotherapy 英国抗生素化疗协会SRGA: Swedish Reference Group for Antibiotics 瑞典抗生素委员会 SFM: Soci ét é Fran çaise de Microbiologie 法国微生物学会注：红色为兽禽用抗生素，绿色为农作物用抗生素，其余为人用抗生素。

乙酰胆碱酯酶抑制剂

上海应用技术学院研究生课程《高等天然产物化学》试卷2014 / 2015 学年第1 学期课程代码：NX0702013论文题目：乙酰胆碱酯酶抑制剂的研究进展姓名：芮银146061414康满满146061409专业：制药工程学院：化工学院乙酰胆碱酯酶抑制剂的研究进展芮银，陈祎桐，康满满摘要：本文阐述了乙酰胆碱酯酶抑制剂(AChEI)的研究进展，介绍了用于药物治疗的乙酰胆碱酯酶抑制剂的各种来源如植物、微生物等，及其抑制乙酰胆碱的活性物质。

在此基础上，总结了几种现代分析技术，对AChEIs进行筛选，大大加快AD药物资源的开发利用进程。

这些方法主要有基于比色法的Ellman's法及相关的改进方法、薄层显色法、荧光显色法、电喷雾质谱法等。

但是，到目前为止，现代分析技术在AD药物资源中的应用还处在起步阶段。

关键词：乙酰胆碱酯酶抑制剂，筛选方法，薄层显色法，荧光显色法The progress of acetylcholinesteraseinhibitorsRui Yin, Chen Yitong, Kang ManmanAbstract：In this artical, the research elaborates progress of acetylcholinesterase inhibitors (AChEI), and introduces a variety of sources for drug treatment acetylcholinesterase inhibitors such as plants, microorganisms, and its active ingredients. On this basis, the review summarizes several modern analytic techniques such as Ellman's method which based on the colorimetric method, TLC chromogenic method, fluorescent color method, Electrospray ionization mass spectrometry and so on. However, at present, the application of modern analytic techniques in AD drug resources is still in infancy.Key word: Acetylcholinesterase inhibitors, Screening Methods, TLC chromogenic method, Fluorescent color method目录摘要.................................................................................................错误!未定义书签。

常见细菌中英文对照、菌组、菌属及代码(革兰阴性部分)

利尼埃放线杆菌
GNCB
放线杆菌属
alm
-
Alteromonas sp.
交替单胞菌属
check
交替单胞菌属
alw
—
Acinetobacter lwoffii
鲁氏不动杆菌
NFR
不动杆菌属
aly
-
Alysiella sp。
小链球菌
check
小链球菌
amd
—
Aeromonas media
中间气单胞菌
FERM
Pasteurella ureae
脲放线杆菌
GNCB
放线杆菌属
ave
—
Aeromonas veronii
维龙气单胞菌
FERM
气单胞菌属
avv
—
Aeromonas veronii biovar veronii
维龙气单胞菌
FERM
气单胞菌属
axy
—
Alcaligenes xylosoxidans
木糖氧化无色杆菌木糖氧化亚种
EBC
志贺菌属
b13
-
Shigella boydii serotype 13
鲍氏志贺菌血清13型
EBC
志贺菌属
b14
-
Shigella boydii serotype 14
鲍氏志贺菌血清14型
EBC
志贺菌属
b15
—
Shigella boydii serotype 15
鲍氏志贺菌血清15型
EBC
志贺菌属
黄褐二氧化碳嗜纤维菌
GNCB
boc
-
Capnocytophaga ochracea

北京索奥生物医药气肿疽梭菌(CC)核酸扩增检测试剂盒说明书

Cat SA-20231CC(DNA)2010第二版1/2气肿疽梭菌(CC)核酸扩增检测试剂盒说明书(PCR-荧光探针法)【名称】中文名：气肿疽梭菌(CC)核酸扩增检测试剂盒英文名：Clostridium Chauvoei Polymerase Chain Reaction (PCR)Diagnostic Kit汉语拼音:qi zhong ju suo jun he suan kuo zeng jian ce shi ji he【目的】本试剂盒适用于检测疑似病牛血液、肌肉肿胀部分泌物液体或组织及淋巴结等组织和环境中疑似污染土壤、饲料及水标本气肿疽梭菌(CC)DNA ，适用于气肿疽梭菌(CC)感染引起的黑腿病的辅助诊断及流行病学调查。

其检测结果仅供参考。

【原理】本试剂盒选取一对气肿疽梭菌(CC)特异性引物和一条特异性荧光探针，通过碱裂解法提取气肿疽梭菌(CC)DNA ，后者在耐热DNA 聚合酶(Taq 酶)作用下，配以FQ-Buffer(内含Mg 2+、Tris-HCl 等)、四种核苷酸单体(dNTPs)等成分，通过PCR-荧光探针体外扩增法对气肿疽梭菌(CC)进行扩增，从而达到实时快速定量检测之目的。

【组成】名称数量规格核酸提取液B4管500μl/管Taq 酶系1管80μl/管CC PCR MIX1管960μl/管CC 阳性质控品1管50μl/管(1×107Copies/ml)阴性质控品1管500μl/管备注：1010××RCLB 另行配备。

【标本采集、保存和运输】1.适用标本类型：疑似病牛血液、肌肉肿胀部分泌物液体或组织及淋巴结等组织和环境中疑似污染土壤、饲料及水标本。

2.标本采集全血：无菌条件下用注射器取人或动物静脉血2-3ml ，转至一含有枸橼酸钠或Na 2EDTA 的抗凝管中，轻轻颠倒数次混匀，立即送检。

肌肉肿胀部分泌物液体：无菌条件下切开肿胀部，注射器吸取液体分泌物2-3ml ，转至一5ml 离心管中，密闭送检。

CAS号26093-31-2_7-氨基-4-甲基香豆素_脉铂技术参数

品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11115
None
Fmoc-Lys-OH
N/A
100g
≥98%
MED11022
乙酰氨基丙二酸二乙酯
Diethyl Acetamidomalonate
1068-90-2
500g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11011
1-羟基-7-偶氮苯并三氮唑
HOAt
39968-33-7
100g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
216.9±24.0 °C
2、同类产品列表：
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11104
N-Fmoc-N'-三苯甲基-D-谷氨酰胺
Fmoc-D-Gln(Trt)-OH
200623-62-7
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
Bio
MED11071
Boc-N'-硝基-L-高精氨酸
Fmoc-Trp-OH
35737-15-6
25g
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11016
2-(1H-苯并[d][1,2,3]三偶氮-1-基)-1,1,3,3-四甲基脲四氟硼酸酯

砜吡草唑代谢物

砜吡草唑代谢物简介砜吡草唑（Sulfapyrazine）是一种广泛用于兽药和人药中的抗菌药物。

使用砜吡草唑治疗感染时，机体会将其代谢成多种代谢物。

本文将对砜吡草唑代谢物进行全面探讨，包括代谢途径、代谢产物以及代谢的影响因素。

代谢途径砜吡草唑的代谢主要通过体内一些酶类来完成。

在动物体内，砜吡草唑首先通过肝脏中的代谢酶进行代谢。

其中主要的酶为CYP2C和CYP2C9。

经过这些酶的作用，砜吡草唑逐步转化为多种代谢物。

代谢产物砜吡草唑的代谢产物包括以下几种：1. 4-羟基砜吡草唑4-羟基砜吡草唑是砜吡草唑最主要的代谢产物之一。

它具有一定的抗菌活性，但与砜吡草唑相比较低。

研究发现，4-羟基砜吡草唑主要由CYP2C9代谢酶催化生成。

2. 5-羧基砜吡草唑5-羧基砜吡草唑是砜吡草唑的另一个重要代谢产物。

与4-羟基砜吡草唑不同，5-羧基砜吡草唑不具有抗菌活性。

它主要由CYP2C代谢酶催化生成。

3. 其他代谢产物除了上述两种代谢产物外，砜吡草唑还可生成一些其他代谢产物，如己氨基砜吡草唑、甲基砜吡草唑等。

这些代谢产物的形成取决于砜吡草唑的浓度、代谢酶的活性以及个体差异等因素。

代谢的影响因素砜吡草唑的代谢受多种因素影响。

下面将详细介绍几个重要的影响因素：1. CYP2C和CYP2C9酶的基因型CYP2C和CYP2C9是砜吡草唑代谢的关键酶。

个体的基因型会对这两个酶的活性产生影响，进而影响砜吡草唑的代谢速率。

研究发现，CYP2C9的多态性与砜吡草唑代谢速率有关，不同基因型的个体代谢砜吡草唑的能力存在差异。

2. 肝功能状态肝脏是砜吡草唑代谢的主要器官，肝功能的健康状态对砜吡草唑的代谢具有重要影响。

肝功能受多种因素影响，如年龄、性别、疾病状态等。

肝功能受损的个体代谢砜吡草唑的能力可能降低，从而引起药物在体内的积累。

3. 药物相互作用砜吡草唑的代谢还受其他药物的影响。

一些药物可以通过竞争性抑制CYP2C和CYP2C9酶的活性，导致砜吡草唑的代谢减慢。